Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase III trial

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide.

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial

Accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: a randomised phase III trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Us…

A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy

Novel Integration of new prostate radiation therapy schedules with adjuvant androgen deprivation

A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer